Related Experiment Video
Updated: Dec 25, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Recent progress in treating advanced prostate cancer
1Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, South Carolina, USA.
Purpose Of Review:
Summarize recent advances in the treatment of advanced prostate cancer.
Recent Findings:
Recent randomized data suggest a survival advantage to early use of novel androgen receptor inhibitors in combination with androgen deprivation therapy both in the setting of hormone-sensitive metastatic prostate cancer and nonmetastatic castration-resistant disease. While ongoing analyses examine optimal sequencing of existing agents for treatment of advanced prostate cancer, additional research focuses on expanding treatment options through development of novel genomically targeted therapies, antibody-drug conjugates, and immune therapy combinations.
Summary:
In this review, we summarize the recent data supporting the early use of novel androgen receptor inhibitors in advanced prostate cancer and aim to also frame how these drugs may fit within the existing context of docetaxel and abiraterone. We present recent series examining sequencing of approved therapies while searching for predictive biomarkers. Finally, we examine trials evaluating novel agents that target certain biological pathways to highlight the likely future directions for progress in the clinical management of advanced prostate cancer.
Insights
Early use of novel androgen receptor inhibitors improves survival in advanced prostate cancer. Research also explores new targeted therapies, antibody-drug conjugates, and immunotherapy combinations for better treatment outcomes.
Area of Science:
- Oncology
- Urology
- Medical Research
Background:
- Advanced prostate cancer treatment has evolved significantly.
- Novel therapies offer new hope for patients with limited options.
Purpose of the Study:
- To review recent advances in treating advanced prostate cancer.
- To discuss the role of novel androgen receptor inhibitors.
- To explore future directions in prostate cancer therapy.
Main Methods:
- Literature review of recent randomized clinical trials.
- Analysis of data on existing and emerging prostate cancer treatments.
- Examination of ongoing clinical trials for novel agents.
Main Results:
- Early use of novel androgen receptor inhibitors with androgen deprivation therapy shows survival benefits.
- Optimal sequencing of current agents is under investigation.
- New genomically targeted therapies, antibody-drug conjugates, and immunotherapies are in development.
Conclusions:
- Novel androgen receptor inhibitors represent a significant advance in advanced prostate cancer care.
- Future treatment strategies will likely involve personalized approaches based on biomarkers and novel drug combinations.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis